Table 3.
Prevalence of HBsAg and anti-HBs in children and young adults after universal vaccination in selected regions.
| Region | Initiation of Universal vaccination | Study period | Age (Y) | No | HBsAg+ (%) | Anti-HBs+ (%) |
|---|---|---|---|---|---|---|
| Alaska, USA116,a | April 1983 | 12/1993–1/1994 | 2–5 | 121 | 0 (0) | 30/120 (25.0) |
| 6–10 | 150 | 0 (0) | 56/146 (38.4) | |||
| 11–15 | 118 | 9 (7.6) | 68/87 (78.2) | |||
| 16–20 | 60 | 11 (18.3) | 28/30 (93.3) | |||
| 21–25 | 62 | 13 (21.0) | 17/21 (81.0) | |||
| 26–30 | 92 | 20 (21.7) | 19/20 (95.0) | |||
| Taiwan117 | 1986 | 1/1/2014–12/31/2014 | <1–29 | 3299 | 17 (0.52) | 1564 (47.4) |
| Singapore118 | 1987 | 8/2008–7/2010 | 1–6 | 400 | 0 (0) | 255 (63.8) |
| 7–12 | 400 | 1 (0.30) | 131 (32.8) | |||
| 13–17 | 400 | 3 (0.75) | 94 (23.5) | |||
| China119 | 2002 | 9/2006–10/2006 | 1–<5 | 13276 | (1.0) | (71.2) |
| 5–<10 | 11909 | (1.4) | (55.5) | |||
| 10–<15 | 11844 | (3.2) | (57.5) | |||
| China120,b | 2002 | 10/2014–12/2014 | >0.6–3 | 1270 | 2 (0.16) | 1210 (95.3) |
| 4–6 | 822 | 3 (0.36) | 733 (89.2) | |||
| 7–9 | 752 | 1 (0.13) | 662 (88.0) | |||
| 10–12 | 598 | 6 (1.00) | 504 (84.3) | |||
| China115 | 2002 | 10/2014–12/2014 | 1–4 | 12681 | (0.3) | (71.6) |
| 5–14 | 9738 | (0.9) | (52.9) | |||
| 15–29 | 9294 | (4.4) | (56.9) |
aThe positive rate of anti-HBs was calculated with fully vaccinated subgroup as denominator.
bThis study defined anti-HBs ≥2 mIU/mL as having immunity to hepatitis B.